Japan-based Takeda Pharmaceutical has signed a contract with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise COUR's CNP-101 (TAK-101), an immune modifying nanoparticle that contains gliadin proteins that is being developed for the treatment of celiac disease, it was reported yesterday.
The deal is worth up to USD420m.
According to the contract, COUR Pharmaceutical Development will be eligible to receive the amount from the Japanese company in the form of future payments, and royalties on sales of any commercialised products emerging from the TAK-101 license. The investigational drug has been developed on COUR's antigen-specific immune tolerance platform. It targets the aberrant immune response in celiac disease, a serious autoimmune disease in which the ingestion of gluten results in inflammation and damage in the small intestine.
Takeda plans to launch a dose-ranging trial to further investigate the potential of TAK-101 in patients with celiac disease on a gluten-free diet.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007